



Published in final edited form as:

*Science*. 2006 November 24; 314(5803): 1304–1308. doi:10.1126/science.1132430.

## Dissecting the Functions of the Mammalian Clock Protein BMAL1 by Tissue-Specific Rescue in Mice

Erin L. McDearmon<sup>1,2</sup>, Kush N. Patel<sup>2</sup>, Caroline H. Ko<sup>2,3</sup>, Jacqueline A. Walisser<sup>4</sup>, Andrew C. Schook<sup>1,2</sup>, Jason L. Chong<sup>2</sup>, Lisa D. Wilsbacher<sup>2</sup>, Eun J. Song<sup>1,2</sup>, Hee-Kyung Hong<sup>1,2</sup>, Christopher A. Bradfield<sup>4</sup>, and Joseph S. Takahashi<sup>1,2,5</sup>

<sup>1</sup>Howard Hughes Medical Institute, Northwestern University, 2205 Tech Drive, Evanston, IL 60208, USA

<sup>2</sup>Department of Neurobiology and Physiology, Northwestern University, 2205 Tech Drive, Evanston, IL 60208, USA

<sup>3</sup>Department of Psychology, University of Toronto, Toronto, Ontario M5S 3G3, Canada

<sup>4</sup>McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI 53706, USA

### Abstract

The bHLH-PAS transcription factor BMAL1 (MOP3) is an essential component of the mammalian circadian pacemaker. *Bmal1*<sup>-/-</sup> mice lose circadian rhythmicity but also display tendon calcification and decreased activity, body weight and longevity. To investigate whether these diverse functions of BMAL1 are tissue-specific, we produced transgenic mice that constitutively express *Bmal1* in brain or muscle, and examined the effects of rescued gene expression in *Bmal1*<sup>-/-</sup> mice. Circadian rhythms of wheel running activity were restored in brain-rescued *Bmal1*<sup>-/-</sup> mice in a conditional manner; however, activity levels and body weight were lower than those of wild-type mice. In contrast, muscle-rescued *Bmal1*<sup>-/-</sup> mice exhibited normal activity levels and body weight yet remained behaviorally arrhythmic. Thus *Bmal1* has distinct tissue-specific functions that regulate integrative physiology.

Circadian rhythms control many aspects of mammalian physiology and behavior. The suprachiasmatic nuclei (SCN) act as pacemakers required for the generation of circadian behavioral rhythms as well as synchronizers of autonomous peripheral tissue clocks (1). Molecular circadian regulation engages a transcription/translation feedback loop comprised of the activating proteins CLOCK and BMAL1, which induce expression of the negative feedback elements *Per* and *Cry* (1). BMAL1 was originally characterized by its high expression in brain and muscle (2, 3) and was identified as a heterodimeric binding partner of CLOCK (4, 5). *Bmal1*<sup>-/-</sup> mice not only lose behavioral circadian rhythmicity, but also exhibit a variety of other phenotypes including decreased activity levels and body weight, progressive joint disease and shortened life span (6–12). Therefore, in addition to circadian rhythm regulation, BMAL1 appears to play a role in a variety of functions that are potentially dependent on the tissue type in which it is expressed. To determine whether BMAL1 has unique tissue-specific functions, we generated transgenic mice that express *Bmal1* ubiquitously or in distinct tissue types. We then crossed these lines onto a *Bmal1* null background and determined which phenotypes could be rescued by exogenous, tissue-specific *Bmal1* expression.

<sup>5</sup>To whom correspondence should be addressed. j-takahashi@northwestern.edu.

We first examined the effects of rescuing *Bmal1* ubiquitously by using a transgenic mouse line produced with *Bmal1*-containing bacterial artificial chromosome (BAC) clones (Fig. 1A, 13). Since the BAC clones contain genomic coding and promoter sequence of *Bmal1*, expression of the transgene should occur in all tissues that normally express *Bmal1*. We measured increased *Bmal1* expression in the SCN of BAC transgenic mice at normal peak and trough times of *Bmal1* mRNA (zeitgeber time (ZT)18 and ZT6, respectively), and also observed increased *Bmal1* expression during peak times in the liver (ZT 18-2) (fig. S1, 13). BAC transgenic mice were then sequentially crossed with *Bmal1*<sup>+/-</sup> mice to produce BAC-rescued *Bmal1*<sup>-/-</sup> mice (13). Circadian rhythms of locomotor activity were then analyzed in a 12h:12h light:dark (LD) cycle followed by constant darkness (DD) conditions (Fig. 1C) (13).

While *Bmal1*<sup>-/-</sup> mice exhibited no circadian rhythm of activity in DD and showed reduced activity levels, BAC-rescued *Bmal1*<sup>-/-</sup> mice displayed normal circadian rhythm characteristics (free-running period and amplitude of circadian rhythm) and activity levels in LD and DD that were similar to wild-type (WT) mice (Fig. 1D). In addition, 100% of BAC-rescued *Bmal1*<sup>-/-</sup> mice survived until the end of experimental analysis (10 months old) compared to 29% of *Bmal1*<sup>-/-</sup> mice. Therefore, long-term survival was restored in the BAC-rescued *Bmal1*<sup>-/-</sup> mice, and no gross abnormalities such as low body weight or joint calcification were observed in the BAC-rescued mice. Thus, *Bmal1* BAC transgenes completely rescued the phenotypes observed in *Bmal1*<sup>-/-</sup> mice.

We next determined whether expression of *Bmal1* in brain tissue could restore behavioral rhythms in *Bmal1*<sup>-/-</sup> mice as well as alleviate other phenotypes. To produce the brain-rescued line, we used the tetracycline transactivator (tTA) system, which requires two transgenes for expression of the target gene, *Bmal1* (see Fig. 2A) (14, 15). We used the promoter sequence of *Scg2*, which is expressed in brain and enriched in the SCN (16), to drive expression of the tetracycline transactivator (*tTA*) (13). The tTA protein binds to the tetracycline operator (tetO) sequence and drives expression of downstream hemagglutinin (HA)-tagged *Bmal1* (*Bmal1*-HA) cDNA. Doxycycline (Dox) inhibits tTA binding to the *tetO* promoter, which halts expression of *Bmal1*-HA. *In situ* hybridization showed strong, specific expression of *Bmal1*-HA in *Scg2::tTA* x *tetO::Bmal1*-HA double transgenic mice only (Fig. 2B, 13). The pattern of expression observed is consistent with high *Scg2* expression in SCN. HA-tagged protein at the correct molecular weight for BMAL1 (~69kD) was produced specifically in double transgenic mouse brain extracts (Fig. 2C), and HA-tagged BMAL1 was shown to be functional by *Per1::luciferase* reporter gene assays (fig. S2, 13). The double transgenic mice were crossed onto *Bmal1*<sup>-/-</sup> background to create brain-rescued *Bmal1*<sup>-/-</sup> mice, and wheel-running experiments were performed as described above (Fig. 2D, fig. S3, S4 and S5).

Adult (8 weeks old) brain-rescued *Bmal1*<sup>-/-</sup> mice exhibited a consistent circadian rhythm of behavior in the initial (pre-Dox) DD period, which was completely abolished after 1–2 days of Dox administration and then regained during Dox withdrawal. However, the free-running period of brain-rescued mice was approximately 1 hour shorter than that of WT (Fig. 2E). This was likely due to the constitutive bioavailability of BMAL1 protein and/or the lack of peripheral tissue feedback to the SCN (fig. S6). In support of this, *Rev-Erba*<sup>-/-</sup> mice express *Bmal1* in the SCN at consistently high levels and exhibit shortened period length (17). In contrast to the restoration of circadian rhythmicity in brain-rescued mice, both amplitude and activity levels were significantly lower than that seen in WT mice (Fig. 2E). Thus, brain-rescued mice exhibit restored circadian rhythms of behavior but their locomotor activity is still impaired.

Because *Bmal1* is highly expressed in muscle, we investigated whether muscle-specific rescue might restore activity levels in *Bmal1*<sup>-/-</sup> mice. We produced muscle-specific *Bmal1* transgenic mice using a DNA construct consisting of human alpha actin-1 (*Acta1*) promoter sequence positioned upstream of *Bmal1*-HA (Fig. 3A, 13). HA-tagged protein was specifically detected in transgenic muscle extracts (Fig. 3B, 13). Adult muscle-rescued *Bmal1*<sup>-/-</sup> mice did not express circadian rhythmicity of activity (Fig. 3C, D); however, their level of locomotor activity was not significantly different from WT mice (Fig. 3D).

We also found that at 4–6 months of age, the *Bmal1*<sup>-/-</sup> and brain-rescued mice weighed significantly less than WT mice. In contrast, the body weight of muscle-rescued mice was restored to a level not significantly different from that of WT mice (Fig. 4A, 13). Only 75% of brain-rescued mice survived to the end of the experiment, whereas 100% of muscle-rescued mice survived. These results suggest that BMAL1 function in muscle is important for activity as well as body weight maintenance and longevity. In addition, bone phenotypes were examined by Alizarin Red stain: both brain and muscle-rescued mice showed significant tendon calcification similar to that seen in *Bmal1*<sup>-/-</sup> mice (Fig. 4B). This suggests that *Bmal1*-HA was not expressed in bone in either line and that the calcification observed in *Bmal1*<sup>-/-</sup> mice was not improved by restoring BMAL1 expression in muscle or brain. Thus, three distinct patterns of rescue could be observed in these mice distinguishing among: 1) circadian activity rhythms; 2) activity level and body weight; and 3) tendon calcification.

Unlike the BAC transgenic line, the brain and muscle transgenic lines were designed to constitutively express BMAL1-HA. To verify this, we measured similar levels of *Bmal1* mRNA and BMAL1-HA protein at normal peak and trough times in the brain and muscle transgenic lines (fig. S6, S7, 13). We then examined mRNA levels of key BMAL1 target genes *Per1* and *Per2* (6). Compared to WT and brain double transgenic mice, *Bmal1*<sup>-/-</sup> mice exhibited consistently low expression levels of *Per1* in the SCN (fig. S7). In contrast, the brain-rescued mice had increased amplitude of *Per1* expression, although peak levels remained significantly lower than WT (fig. S7). *Per2* expression was measured in both muscle and liver from the brain and muscle transgenic lines at normal peak time for *Per2* (ZT12) (fig. S8, 13). *Per2* in muscle of *Bmal1*<sup>-/-</sup> mice was significantly reduced to below 50% WT levels at ZT12. This decreased expression was restored to WT levels in the muscle-rescued mice but not in the brain-rescued mice. These data suggest that the presence of BMAL1 is important for proper expression of *Per1* genes in brain and muscle tissue (but not liver, see fig. S8). Both *Rev-Erb $\alpha$*  and *Dbp* exhibited dramatic downregulation in liver and muscle of *Bmal1*<sup>-/-</sup> mice at ZT12 and showed increased expression only in muscle of muscle-rescued mice (fig. S8).

In conclusion, we have shown that all phenotypes of *Bmal1*<sup>-/-</sup> mice are alleviated only when *Bmal1* is rescued ubiquitously, whereas different parameters of behavioral activity (circadian rhythm and activity level), body weight and gene expression can be rescued separately by distinct spatial expression patterns of *Bmal1*. Genome-wide profiling experiments suggest that ~10% of the transcriptome is under circadian regulation; however, the majority of these cycling transcripts are tissue-specific (18–22). Our results are consistent with this tissue-specific diversity of circadian expression and further suggest that core circadian clock components may play distinct roles in different tissues, perhaps in addition to their function in regulating circadian rhythms. The restoration of circadian activity rhythms in brain-rescued *Bmal1*<sup>-/-</sup> mice is consistent with previous SCN transplant studies in rodents (23, 24). However, the transgenic approach used here has the advantages of preserving the anatomical integrity of the brain as well as allowing the conditional manipulation of the rescue via Dox treatment. The use of tissue-specific and conditional

regulation of circadian clock gene expression should be a valuable method for understanding the molecular-, cellular- and systems-level regulation of circadian rhythms in mammals.

## Supplementary Material


Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank N. Lampl, A. Jyawook and A. Falk for technical assistance; members of the Takahashi laboratory and F. Davis for expert advice and K. Esser, E. Hardeman and M. Mayford for the kind gifts of plasmids. Supported by NIH grants R01 ES005703 to C.A.B. and P50 MH074924 to J.S.T.


## References

1. Lowrey PL, Takahashi JS. *Annu Rev Genomics Hum Genet.* 2004; 5:407. [PubMed: 15485355]
2. Ikeda M, Nomura M. *Biochem Biophys Res Commun.* 1997; 233:258. [PubMed: 9144434]
3. Hogenesch JB, et al. *J Biol Chem.* 1997; 272:8581. [PubMed: 9079689]
4. Gekakis N, et al. *Science.* 1998; 280:1564. [PubMed: 9616112]
5. Hogenesch JB, Gu YZ, Jain S, Bradfield CA. *Proc Natl Acad Sci U S A.* 1998; 95:5474. [PubMed: 9576906]
6. Bunger MK, et al. *Cell.* 2000; 103:1009. [PubMed: 11163178]
7. Rudic RD, et al. *PLoS Biol.* 2004; 2:e377. [PubMed: 15523558]
8. Bunger MK, et al. *Genesis.* 2005; 41:122. [PubMed: 15739187]
9. Laposky A, et al. *Sleep.* 2005; 28:395. [PubMed: 16171284]
10. Shimba S, et al. *Proc Natl Acad Sci U S A.* 2005; 102:12071. [PubMed: 16093318]
11. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. *Genes Dev.* 2006; 20:1868. [PubMed: 16847346]
12. Sun Y, et al. *J Biomed Sci.* 2006
13. Please see Supplementary Online Material
14. Gossen M, Bujard H. *Proc Natl Acad Sci U S A.* 1992; 89:5547. [PubMed: 1319065]
15. Furth PA, et al. *Proc Natl Acad Sci U S A.* 1994; 91:9302. [PubMed: 7937760]
16. Hong H, et al. *Society for Research on Biological Rhythms Abstracts.* 2006; 10:30.
17. Preitner N, et al. *Cell.* 2002; 110:251. [PubMed: 12150932]
18. Kornmann B, Preitner N, Rifat D, Fleury-Olela F, Schibler U. *Nucleic Acids Res.* 2001; 29:E51-1. [PubMed: 11376163]
19. Akhtar RA, et al. *Curr Bio.* 2002; 12:540. [PubMed: 11937022]
20. Panda S, et al. *Cell.* 2002; 109:307. [PubMed: 12015981]
21. Ueda HR, et al. *Nature.* 2002; 418:534. [PubMed: 12152080]
22. Storch KF, et al. *Nature.* 2002; 417:78. [PubMed: 11967526]
23. Ralph MR, Foster RG, Davis FC, Menaker M. *Science.* 1990; 247:975. [PubMed: 2305266]
24. Sujino M, et al. *Curr Bio.* 2003; 13:664. [PubMed: 12699623]



**Fig. 1.** *Bmal1*-containing BAC transgenes rescue *Bmal1*<sup>-/-</sup> phenotypes. (A) *Bmal1* BAC clones were used to create transgenic (Tg) mice, which were consecutively crossed with *Bmal1*<sup>+/-</sup> mice to create BAC-rescued *Bmal1*<sup>-/-</sup> mice. (B) *Bmal1* mRNA levels in SCN were examined by *in situ* hybridization in wild-type (WT) and *Bmal1* BAC Tg mice, sacrificed at ZT6 and ZT18 (shown are mean  $\pm$  SEM; significant effect of genotype, GLM ANOVA). (C) Representative wheel-running activity records from WT, *Bmal1* BAC Tg, *Bmal1*<sup>-/-</sup> (*Bmal1* KO) or BAC-rescued (*Bmal1* BAC Tg; *Bmal1* KO) mice. Mice were housed in LD then released into DD for 3 weeks. (D) Bar graphs of mean  $\pm$  SEM show that BAC-rescued mice (n=6) exhibit free-running period, amplitude of circadian rhythm and activity levels that are


not significantly different from WT. Amplitude is graphed as the peak amplitude of the proportion of the total variance in the time series in the circadian (~24h) range (\*\*p<0.001, one-way ANOVA; \*significant effect of genotype, GLM ANOVA).




**Fig. 2.** Reversible restoration of circadian rhythms but not activity levels in brain-rescued *Bmal1*<sup>-/-</sup> mice. (A) Mice were created to express *Bmal1*-HA conditionally in brain tissue by using the tTA system. (B) *In situ* hybridization was performed with HA tag or *Bmal1* probes on brains from WT, *tetO::Bmal1*-HA (*tetO*), or *Scg2::tTA x tetO::Bmal1*-HA double transgenic (DTg) mice sacrificed at ZT 6 (arrow indicates SCN, scale bar is 1mm). (C) Western blot showing HA staining in brain, liver and skeletal muscle protein extracts from WT or DTg mice sacrificed at ZT 12 (arrow indicates correct size of BMAL1). (D) Representative wheel-running activity records from one *Bmal1*<sup>-/-</sup> mouse and two brain-rescued *Bmal1*<sup>-/-</sup> (DTg; *Bmal1* KO) mice. After 3 weeks in DD (Pre), mice were administered Dox for 2

weeks (Dox, highlighted yellow) and then spent an additional 3 weeks without Dox (Post). (E) Brain-rescued mice (n=10) display a free-running period of 22.8 h (Pre) and 22.6 h (Post) when *Bmal1* is expressed, which are significantly different from WT and DTg groups (\*significant effect of genotype, GLM ANOVA). Activity levels of KO and DTg KO mice were significantly reduced compared to WT. Amplitude of circadian rhythm was significantly different in all genotypes compared to WT, and a simultaneous loss of rhythm and decrease in amplitude were observed in DTg KO mice during Dox treatment (†significant effect of time interval). Graphs represent the mean  $\pm$  SEM.





**Fig. 3.** Muscle-rescued mice exhibit restored activity level but not circadian rhythms. (A) Muscle-specific *Bmal1* Tg mice were created by fusing the *Acta1* promoter sequence to *Bmal1*-HA. (B) Western blot shows HA staining in brain, liver and skeletal muscle protein extracts from WT or Tg mice sacrificed at ZT 12 (arrow indicates correct size of BMAL1). (C) Representative wheel-running activity records are shown from WT, Tg, *Bmal1* KO, and muscle-rescued (Tg; *Bmal1* KO) mice. (D) Muscle-rescued mice (n=6) are arrhythmic in DD with significantly reduced amplitude of rhythm (\*\*p<0.01, one-way ANOVA), but display activity levels that are not significantly different from WT mice. Graphs show mean ± SEM (\*significant effect of genotype, GLM ANOVA).



**Fig. 4.** Effects of tissue-specific *Bmal1* expression on body weight and tendon calcification. (A) Brain-rescued mice and KO mice in both lines have significantly reduced body weight, while muscle-rescued mice exhibit similar body weight to WT mice (graphs represent mean + SEM; \*\* $p < 0.01$  \*\*\* $p < 0.001$ , one-way ANOVA). (B) Photographs of Alizarin Red-stained hind limbs from WT, KO, muscle and brain-rescued KO mice are shown. Arrows indicate calcaneal tendon calcification in all but WT mice.